SCHEMBL7945065

SCHEMBL7945065

COCCCOc1ccc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)nc1

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 18/20 0.53
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
BACE2 Q9Y5Z0 5/20 0.42
GRM4 Q14833 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7943122 0.96 BACE1 (0.58) BACE1AURKAAURKBBACE2GRM4
SCHEMBL7944561 0.91 BACE1 (0.49) BACE1AURKAAURKBBACE2
SCHEMBL7944850 0.91 BACE1 (0.56) BACE1AURKAAURKBBACE2
SCHEMBL12301454 0.91 BACE1 (0.51) BACE1AURKAAURKBBACE2
SCHEMBL7935468 0.87 BACE1 (0.48) BACE1AURKAAURKBBACE2
SCHEMBL7941874 0.87 BACE1 (0.60) BACE1AURKAAURKBBACE2
SCHEMBL7941722 0.86 BACE1 (0.51) BACE1BACE2GRM4
SCHEMBL7935750 0.85 BACE1 (0.56) BACE1GRM4
SCHEMBL7941843 0.85 BACE1 (0.72) BACE1AURKAAURKB
SCHEMBL7944814 0.85 BACE1 (0.52) BACE1AURKAAURKBBACE2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885AURKA 3552/4885AURKB 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.